Suchergebnisse

Presentation by Christoph Steinbeck at the workshop hosted by the PhenoMeNal consortium to define the state-of-the-art in Metabolic Phenotyping in the Clinic. The event was attended by a mixed audience from medical/clinical, industry or commercial, government, working or collaborating using metabolomics data and tools and technologies related to clinic.

Proceedings of: The 6th International Workshop on Semantic Web Applications and Tools for Life Sciences (SWAT4LS 2013). Took place 2013, December 11-12, in Edinburgh, UK. The evnt Web site http://www.swat4ls.org/workshops/edinburgh2013/ ; Drug-drug interactions form a significant risk group for adverse effects associ-ated with pharmaceutical treatment. These interactions are often reported in the literature, however, they are sparsely represented in machine-readable re-sources, such as online databases, thesauri or ontologies. These knowledge sources play a pivotal role in Natural Language Processing (NLP) systems since they provide a knowledge representation about the world or a particular do-main. While ontologies for drugs and their effects have proliferated in recent years, there is no ontology capable of describing and categorizing drug-drug in-teractions. Moreover, there is no artifact that represents all the possible mecha-nisms that can lead to a DDI. To fill this gap we propose DINTO, an ontology for drug-drug interactions and their mechanisms. In this paper we describe the classes, relationships and overall structure of DINTO. The ontology is free for use and available at https://code.google.com/p/dinto/ ; This work was supported by the Regional Government of Madrid under the Research Network MA2VICMR [S2009/TIC-1542], by the Spanish Ministry of Education under the project MULTIMEDICA [TIN2010-20644-C03-01] and by the European Commission Seventh Framework Programme under the project TrendMiner_Enlarged (EU FP7-ICT 612336). ; Publicado

© The Author(s), 2012. This article is distributed under the terms of the Creative Commons Attribution License. The definitive version was published in Nature Genetics 44 (2012): 121-126, doi:10.1038/ng.1054. ; To make full use of research data, the bioscience community needs to adopt technologies and reward mechanisms that support interoperability and promote the growth of an open 'data commoning' culture. Here we describe the prerequisites for data commoning and present an established and growing ecosystem of solutions using the shared 'Investigation-Study-Assay' framework to support that vision. ; The authors also acknowledge the following funding sources in particular: UK Biotechnology and Biological Sciences Research Council (BBSRC) BB/I000771/1 to S.-A.S. and A.T.; UK BBSRC BB/I025840/1 to S.-A.S.; UK BBSRC BB/I000917/1 to D.F.; EU CarcinoGENOMICS (PL037712) to J.K.; US National Institutes of Health (NIH) 1RC2CA148222-01 to W.H. and the HSCI; US MIRADA LTERS DEB-0717390 and Alfred P. Sloan Foundation (ICoMM) to L.A.-Z.; Swiss Federal Government through the Federal Office of Education and Science (FOES) to L.B. and I.X.; EU Innovative Medicines Initiative (IMI) Open PHACTS 115191 to C.T.E.; US Department of Energy (DOE) DE-AC02- 06CH11357 and Arthur P. Sloan Foundation (2011- 6-05) to J.G.; UK BBSRC SysMO-DB2 BB/I004637/1 and BBG0102181 to C.G.; UK BBSRC BB/I000933/1 to C.S. and J.L.G.; UK MRC UD99999906 to J.L.G.; US NIH R21 MH087336 (National Institute of Mental Health) and R00 GM079953 (National Institute of General Medical Science) to A.L.; NIH U54 HG006097 to J.C. and C.E.S.; Australian government through the National Collaborative Research Infrastructure Strategy (NCRIS); BIRN U24-RR025736 and BioScholar RO1-GM083871 to G.B. and the 2009 Super Science initiative to C.A.S.